Breaking AI & Tech News Analyzed

Breathing Earth's Ancient PastMore than 2bn years ago, during the Paleoproterozoic era, the Earth's atmosphere began to fill with free oxygen, enabling the rise of aerobic life and, ultimately, humans. This Great Oxidation Event is now being experienced firsthand by visitors to the Museum of Old and New Art (Mona) in Tasmania, where French-Swiss conceptual artist Julian Charrière has created an extraordinary installation that allows people to inhale oxygen that has been trapped in iron ore since that ancient time.When Charrière came up with the concept for what would become 'Breathe,' Mona's owner David Walsh not only approved the project but created a bespoke space for it, recognizing the unique intersection of science, art, and human experience that the installation represents.The Science Behind the Ancient OxygenThe installation is a marvel of scientific ingenuity and artistic vision. Charrière has sourced ancient iron ore from Australia's Pilbara region, which is processed daily in an on-site laboratory. The water is extracted from the ore using specialized machinery, then put through a Hofmann apparatus—a piece of scientific equipment that electrolyzes water—to liberate the trapped oxygen molecules.This pure, ancient oxygen is then released into a specially designed room where visitors can breathe it in, creating a direct connection to the beginning of life on Earth. As Charrière explains: 'I want people to get all the way back to the beginning of the earth. It's like a time machine.' The installation is designed as a solitary experience, with visitors accessing a vault-like corridor reminiscent of a mining drift, flanked by raw sandstone and lined with deep red rocks from the Pilbara.The Immense Timescale of the InstallationThe timescale involved in 'Breathe' is almost incomprehensible. The oxygen visitors inhale has been trapped in iron ore for over 2.4 billion years—since the Great Oxidation Event that transformed Earth's atmosphere and enabled the development of complex life forms. This installation literally connects each visitor to the primordial beginnings of our planet's atmosphere.As visitors walk through the tunnel, the temperature drops as they approach a high-ceilinged cylindrical room, an underground windowless tower where lighting depends on the amount of sun that can be reflected through a small opening above. Walking over tiles made of polished ancient tiger ore, they circle a floor-to-ceiling clear glass tube that houses the Hofmann apparatus. It is here, at a small opening, that visitors have their closest access to Charrière's pure, ancient oxygen.Redefining the Art-Science Experience'Breathe' represents a groundbreaking fusion of scientific methodology and artistic expression, challenging traditional boundaries between disciplines. The installation creates a profound personal experience that connects visitors not just to art, but to the very essence of life on Earth.What makes this installation particularly powerful is its claim that each visitor is the first human being to ever inhale that specific oxygen. As Charrière explains: 'You are breathing something which is so pure and has not been touched by any being before you... And the beauty of the piece is you will carry it until you die. You're going to become a small part of this installation and you become a big part of the great oxygen cycle, and you will only finally free this oxygen once... once you're going in the other world.'This installation is part of a broader trend in contemporary art that incorporates scientific processes and concepts, creating works that are both intellectually stimulating and viscerally impactful.The Future of Scientific Art Installations'Breathe' is opening alongside Charrière's major new exhibition 'Hard Core,' which showcases both the ambition and scientific curiosity of the Berlin-based artist. Individual elements of 'Hard Core' have been exhibited elsewhere in the world, including at the Venice Biennale, but the full exhibition finds its perfect home at Mona, with its exposed rock, industrial aesthetic, and fusion of science with art.As museums and galleries continue to seek innovative ways to engage audiences, installations like 'Breathe' point to a future where art and science are not just displayed together but are fundamentally intertwined in the creative process. This approach has the potential to create more immersive, educational, and thought-provoking experiences that challenge visitors to see the world—and their place in it—in new ways.Charrière's work demonstrates how art can make abstract scientific concepts tangible and personal, creating connections across vast stretches of time and space. As our understanding of the universe expands, art installations like 'Breathe' will play an increasingly important role in helping us process and relate to these profound concepts.

The Leap: Conversational Access to Quantitative Drug‑Discovery ModelsIn a bold move to democratize high‑performance chemistry, SandboxAQ has integrated its proprietary large quantitative models (LQMs) into Anthropic’s conversational AI, Claude. The partnership eliminates the need for users to provision costly computing resources, allowing scientists to query complex quantum‑chemistry simulations in natural language.SandboxAQ Teams with Anthropic to Embed LQMs in ClaudeThe five‑year‑old Alphabet spin‑out, chaired by Eric Schmidt, announced the integration after raising $950 million from investors. The LQMs are “physics‑grounded,” meaning they are built on scientific equations and real‑world lab data rather than purely on text patterns. They can perform quantum chemistry calculations, molecular‑dynamics runs, and micro‑kinetics simulations, delivering predictions about candidate molecules before any wet‑lab work begins.Financial and Market Scale of the Quantitative Economy$950 million raised to date by SandboxAQ.The company positions its LQMs within a $50+ trillion quantitative economy spanning biopharma, finance, energy, and advanced materials.Traditional drug‑discovery projects can cost billions of dollars and take a decade to yield a viable molecule.Why a Conversational Interface Could Disrupt Pharma R&D;Historically, only computationally sophisticated teams could leverage large‑scale chemistry models, requiring on‑premise GPUs or cloud clusters. By surfacing these capabilities through natural‑language chat, SandboxAQ lowers the barrier for:Computational scientists seeking rapid hypothesis testing.Experimentalists who lack deep AI‑infrastructure expertise.Large pharmaceutical and industrial firms aiming to accelerate material discovery.Customers have reported that existing software failed to translate complex problems into actionable results, a gap SandboxAQ hopes to fill.Future Outlook: Scaling AI‑Driven Chemistry Across IndustriesWith the Claude integration, SandboxAQ expects broader adoption beyond pharma, extending into energy, finance, and advanced materials where quantitative simulations are critical. As more firms adopt conversational AI for scientific workflows, the competitive advantage will shift from model performance to usability and integration speed. The next wave may see LQMs embedded in other enterprise assistants, further blurring the line between AI chat and high‑performance scientific computing.

The Legacy of a Scientific Pioneer My husband Peer Bork, who has died unexpectedly aged 62, was a bioinformatician with a remarkable ability to identify new directions in science and carry out world-class research to push them forward. Revolutionizing Microbiome Research During his career, he progressed from the statistical analysis of the sequences of individual protein molecules, via the analysis of the human genome, to the bioinformatics analysis of whole microbial communities. Peer pioneered the computational analysis of the human microbiome, introducing the concept of gut enterotypes – in work that was highlighted in many newspaper articles as well as on the radio and TV. He went on to study microbial ecosystems worldwide and, at the time of his death, was involved in expanding a consortium that he had initiated to systematically document coastal ecosystems in Europe. All these studies required the creation of bioinformatics tools – software and curated datasets – which are now widely used by the scientific community in academia and industry. A Life in Science Peer was born in the former East Berlin, where his father, Joachim, worked in economic statistics, and his mother, Regina, had an administrative job in the construction industry. Owing to his mathematical abilities, he won a place at a high school specialising in mathematics and science, the Heinrich-Hertz-Oberschule. After military service on the border between East and West Germany, he studied biochemistry at the University of Leipzig. He followed this with a PhD in bioinformatics under the supervision of Jens Reich at the Central Institute for Molecular Biology of the Academy of Sciences of the GDR in Berlin. International Scientific Career After the fall of the Berlin Wall in 1989, Peer joined the European Molecular Biology Laboratory (EMBL) in Heidelberg in 1991 as a visiting scientist. He and I met there and married in Canterbury, Kent, in 1994. We had two sons, Udo and Robin, and family life involved many trips between Germany and Britain. EMBL became Peer's scientific home and he rose up the ranks to become interim director general in 2025. He was dedicated to furthering EMBL – an intergovernmental research organisation with six sites, including the European Bioinformatics Institute near Cambridge. He was an outstanding mentor. Awards and Recognition He made science both challenging and fun. Among his awards, which included honorary doctorates and the 2009 Royal Society and Académie des Sciences Microsoft award, he was particularly proud of the Nature award for mentoring in science he received in 2008. Final Scientific Journey He died in Taiwan, where he was due to speak at an international conference on the microbiome. He loved to travel and make friends all over the world. Peer is survived by me, his sons, by a granddaughter and his mother.

What sparked Twitch’s policy shift on “mog‑off” contestsAfter a viral wave of Omoggle matches—where users are pitted against strangers in a 1v1 “mog‑off” based on facial metrics—Twitch announced on Tuesday, 2026‑05‑10 that it would allow participation in “current trends” like the game, despite earlier bans on random video‑chat services.Omoggle’s facial‑recognition scoring system and its viral surgeOmoggle, built on the defunct Omegle matching engine, analyses features such as canthal tilt, palpebral fissure ratio, and nose‑to‑face width. Scores range from 1 to 10 on the “PSL” (Perceived Sexual Market Value) scale, a term borrowed from incel forums. The platform assigns an Elo‑style rank, with tiers like “sub3,” “normie,” and the newly added “molecule.”Scale of participation and potential revenue implicationsThousands of concurrent players at any moment, according to internal Omoggle metrics.One user, Sammy Amz, reported a 200‑win streak within a week of starting.Major UK streamers have incorporated mog‑offs into their broadcasts, driving higher viewer counts and ad revenue.While Twitch has not disclosed direct financial impact, the surge in viewership suggests a measurable uplift for creators who adopt the format.Implications for platform moderation and youth cultureModerators face a dilemma: the game itself is not prohibited, but random video matches can expose audiences to explicit content. Twitch advises streamers to “quickly remove” themselves by switching scenes if inappropriate material appears. Psychologist Dr Paul Marsden warns that the PSL system is “nonsense” but reflects a broader societal shift toward quantifying personal value.Future of gamified looks‑maxxing on live‑streaming servicesAnalysts predict that other platforms will follow Twitch’s permissive stance, integrating similar gamified “looks‑maxxing” tools while investing in AI‑driven moderation. As Gen Z continues to meme‑ify self‑assessment, the line between harmless entertainment and harmful obsession may blur, prompting ongoing debate among creators, regulators, and mental‑health experts.

The Hidden Charge in Volcanic AshFor decades, scientists have been baffled by the presence of lightning in volcanic plumes, which are typically dry and devoid of the ice crystals found in storm clouds. The prevailing theory suggested that volcanic particles, being made of the same rocky material, should not generate the necessary charge separation to create electrical arcs. However, a groundbreaking study published in Nature by the Institute of Science and Technology Austria has revealed that the secret lies not in the rock itself, but in a microscopic coating of carbon-rich molecules.Mechanism of the SparkThe research demonstrates that while perfectly clean silica particles do not tend to pick up charge, the introduction of a carbon coating triggers significant charge transfer during collisions. This phenomenon can occur simply through the heating of silica, as normal air contains enough carbon-containing molecules to create surface contamination. The intense heat and updrafts of a volcanic eruption provide the perfect environment for this charging mechanism to occur, effectively turning the ash plume into a massive electrical generator.The Power of the Hunga Tonga EruptionThe significance of this discovery is best illustrated by the Hunga Tonga-Hunga Ha‘apai eruption in 2022, which served as a real-world test case for the new theory. The event produced a staggering display of atmospheric electricity that defied previous understanding of dry plume behavior.Intensity: The eruption generated over 2,600 lightning flashes per minute.Height: Electrical discharges stretched up to 19 miles (31km) above sea level.Environment: The plume was composed primarily of dry ash and rock fragments, yet it exhibited the same electrical properties as wet thunderstorms.Redefining Atmospheric PhysicsThis breakthrough fundamentally alters our understanding of atmospheric electricity. It confirms that the rules governing lightning generation extend beyond water and ice to include the complex chemistry of volcanic particles. By identifying the carbon coating as the catalyst, scientists now have a clear physical model to explain why dry volcanic eruptions can be as electrically active as the most violent thunderstorms.Future Volcanic MonitoringWith the mechanism now understood, this knowledge offers new tools for volcanic monitoring and safety. The presence of lightning can now be more accurately predicted based on the composition and temperature of the volcanic plume. This insight allows for better forecasting of eruption intensity and potential hazards, bridging the gap between geological activity and atmospheric physics.

The 'Characterization Bottleneck' in Biotech While AI models like Google DeepMind's AlphaFold have revolutionized the field by predicting protein structures with unprecedented accuracy, they have inadvertently created a new problem: an overwhelming flood of potential drug candidates. The industry is now facing a critical bottleneck where the supply of AI-generated hypotheses far outstrips the capacity to physically characterize and test them. 10x Science was founded specifically to address this gap, aiming to streamline the transition from digital prediction to physical validation. 10x Science Raises $4.8M to Automate Mass Spectrometry The startup announced a $4.8 million seed round today, led by Initialized Capital and backed by Y Combinator, Civilization Ventures, and Founder Factor. The three founders—David Roberts and Andrew Reiter, experienced biochemists, and Vishnu Tejas, a serial founder in computer science—previously worked together in the Stanford lab of Nobel laureate Dr. Carolyn Bertozzi. Frustrated by the inability to understand molecular interactions precisely, they built a platform that combines deterministic chemistry algorithms with AI agents capable of interpreting complex data. Founding Team: David Roberts, Andrew Reiter, and Vishnu Tejas. Seed Round: $4.8 million led by Initialized Capital. Key Differentiator: Traceable analysis to meet regulatory compliance standards. Accelerating Molecular Analysis with AI Agents The core value proposition of 10x Science lies in its ability to democratize mass spectrometry, a technique traditionally requiring expensive equipment and deep expertise. By training models on vast amounts of spectrometry data, the platform allows researchers to bypass the 'can of worms' of manual data interpretation. Matthew Crawford, a scientist at Rilas Technologies, notes that the AI not only speeds up analysis but also adapts to different molecules and can infer protein identities from file names, significantly reducing manual programming effort. Democratizing High-End Chemical Analysis for Biopharma 10x Science is positioning itself as a SaaS platform that pharma companies must subscribe to for ongoing compliance and efficiency. Unlike traditional biotech investments that rely on a single drug succeeding, 10x offers a recurring revenue model based on the utility of the tool itself. The platform helps researchers who lack the resources to deploy expensive spectrometry equipment, allowing them to focus on the next steps in research rather than getting bogged down in complex data analysis. The Future of 'Molecular Intelligence' in Drug Development Looking ahead, 10x Science aims to expand beyond simple characterization to offer a new definition of 'molecular intelligence.' By combining protein structure data with other cellular metrics, the company hopes to provide a holistic view of biology. Investors like Zoe Perret at Initialized Capital believe the deep domain expertise of the founders will protect the company from competitors, as the intersection of chemistry, biology, and AI remains a highly specialized niche.

Researchers from the Swedish University of Agricultural Sciences have demonstrated that trace amounts of cocaine and its primary breakdown product, benzoylecgonine, can alter the movement and activity of juvenile Atlantic salmon released in Lake Vättern, Sweden’s second‑largest lake. Key Developments Two‑year‑old hatchery‑reared salmon were implanted with devices releasing environmentally realistic concentrations of cocaine or benzoylecgonine; a control group received drug‑free implants. All fish were equipped with acoustic transmitters and released into the south‑west corner of Lake Vättern (≈ 2,000 sq km). Over a two‑month tracking period, drug‑exposed salmon showed heightened activity toward the study’s end. In the final two weeks, cocaine‑exposed fish swam 5 km farther than controls; metabolite‑exposed fish swam 14 km farther – roughly double the distance. Metabolite‑exposed salmon also moved 12 km farther north than unexposed fish, indicating a stronger behavioural impact. Data & Market Impact Average daily movement increase: +5 km (cocaine) and +14 km (benzoylecgonine) compared with control. Spatial expansion represents a ~150‑200% increase in range for metabolite‑exposed fish. Potential ecosystem cost: altered predator‑prey dynamics could affect commercial fisheries valued at several hundred million euros in the region. Why This Matters Salmon that expend more energy traveling farther may experience reduced growth rates, impacting both wild populations and aquaculture operations. Increased exposure to open‑water zones raises predation risk, potentially lowering survival rates and affecting biodiversity. Drug residues entering waterways stem largely from raw sewage overflows, highlighting a gap in current wastewater‑treatment efficacy. Findings underscore a broader, under‑recognized threat: pharmaceutical metabolites can act as ecological stressors comparable to traditional pollutants. Expert Insight Dr Jack Brand emphasizes that the metabolite’s stronger effect suggests risk assessments that ignore degradation products may vastly underestimate environmental harm. Prof Leon Barron of Imperial College London points out the need for field validation, noting that laboratory‑derived behavioural shifts must be corroborated in naturally polluted habitats. Both scientists agree that improved wastewater infrastructure—particularly the reduction of raw sewage discharges—could mitigate exposure, while pharmaceutical manufacturers are urged to develop “green” drugs that break down harmlessly. What Happens Next Regulators may expand monitoring programs to include illicit‑drug metabolites alongside conventional contaminants. Further field studies are likely to assess whether similar behavioural changes occur in other species such as trout and perch. Policy pressure could accelerate the adoption of advanced treatment technologies (e.g., ozonation, activated carbon) capable of removing benzoylecgonine. Pharmaceutical firms might face incentives—or mandates—to design molecules with rapid, benign degradation pathways.

NASA’s Curiosity rover has identified five previously unseen organic molecules in a dried lakebed near Mars’ equator, confirming the presence of complex carbon‑based chemistry that has persisted for roughly 3.5 bn years. The discovery, published in Nature Communications, fuels debate over whether these compounds are remnants of ancient life or products of geological processes. Key Developments Five new organic molecules detected in a dried lakebed within Gale crater. Identification of benzothiophene and a nitrogen‑bearing precursor structurally similar to DNA building blocks. Scientists emphasize that the organics could be either biogenic or delivered by meteorites. Prof Amy Williams (University of Florida) notes the preservation of organics for 3.5 bn years despite harsh radiation. Findings published in Nature Communications and linked to upcoming ESA Rosalind Franklin mission (launch 2028). Data & Market Impact NASA’s Curiosity program cost approximately $2.5 billion over its decade‑long operation. The European Space Agency’s Rosalind Franklin rover, slated for a 2028 launch, carries a budget of roughly €1.3 billion, reflecting growing international investment in Mars exploration. Increased public and private interest (e.g., SpaceX’s Mars ambitions) is driving a surge in funding for planetary science, with global space‑related R&D; spending projected to exceed $150 billion by 2030. Why This Matters Confirms that complex organics can survive Mars’ radiation, expanding the window for detecting biosignatures. Strengthens the scientific case for sample‑return missions, which could finally distinguish biogenic from abiotic origins. Boosts public enthusiasm and political support for continued investment in planetary science. Provides a comparative baseline for Earth’s early chemistry, informing models of how life originated on our planet. Impacts planetary protection protocols by highlighting the persistence of organics that could contaminate future missions. Expert Insight The detection of benzothiophene—a sulphur‑rich compound commonly delivered by carbonaceous meteorites—suggests that exogenous delivery played a significant role in seeding Mars with pre‑biotic material. However, the nitrogen‑bearing molecule’s structural similarity to DNA precursors hints at in‑situ synthesis pathways that may have operated under ancient Martian conditions. The coexistence of both exogenous and endogenous organics challenges the simplistic “meteorite‑only” narrative and points to a more complex pre‑biotic chemistry that could have supported microbial ecosystems during the planet’s habitable window (approximately 3.7–4.1 bn years ago). What Happens Next The ESA Rosalind Franklin rover will drill up to 2 m below the surface, enabling isotopic analyses that can discriminate between biological and geological origins. NASA’s planned Mars Sample Return campaign, targeting a 2028 launch, will retrieve curated rock cores for Earth‑based laboratory study, potentially providing definitive evidence of past life. International collaborations are likely to intensify, with joint data‑sharing agreements that could accelerate the timeline for a conclusive answer. Policy makers may leverage these findings to justify increased budgets for astrobiology research and to refine planetary protection standards for future human missions.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”